These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20335450)

  • 21. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly.
    Bhayana S; Booth GL; Asa SL; Kovacs K; Ezzat S
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6290-5. PubMed ID: 16118335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.
    Ishibashi M; Yamaji T
    J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining Cadherin Expression with Molecular Markers Discriminates Invasiveness in Growth Hormone and Prolactin Pituitary Adenomas.
    Chauvet N; Romanò N; Meunier AC; Galibert E; Fontanaud P; Mathieu MN; Osterstock G; Osterstock P; Baccino E; Rigau V; Loiseau H; Bouillot-Eimer S; Barlier A; Mollard P; Coutry N
    J Neuroendocrinol; 2016 Feb; 28(2):12352. PubMed ID: 26686489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas.
    Qian ZR; Sano T; Yoshimoto K; Asa SL; Yamada S; Mizusawa N; Kudo E
    Mod Pathol; 2007 Dec; 20(12):1269-77. PubMed ID: 17873891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
    J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and significance of E-cadherin and β-catenins in pituitary adenoma.
    Zhou K; Jin H; Luo Y
    Int J Surg Pathol; 2013 Aug; 21(4):363-7. PubMed ID: 23349466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
    Melmed S; Sternberg R; Cook D; Klibanski A; Chanson P; Bonert V; Vance ML; Rhew D; Kleinberg D; Barkan A
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4405-10. PubMed ID: 15827109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathobiology of pituitary adenomas and carcinomas.
    Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
    Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro.
    Klibanski A; Alexander JM; Bikkal HA; Hsu DW; Swearingen B; Zervas NT
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1248-55. PubMed ID: 1720125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic value of the Knosp scale in trans-sphenoidal surgery for pituitary adenomas].
    Zieliński G; Podgórski JK
    Neurol Neurochir Pol; 2002; 36(1):69-82. PubMed ID: 12053617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
    Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
    J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995.
    Ducasse MC; Tauber JP; Tourre A; Bonafe A; Babin T; Tauber MT; Harris AG; Bayard F
    J Clin Endocrinol Metab; 1987 Nov; 65(5):1042-6. PubMed ID: 2889748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary.
    Yamada S; Sano T; Stefaneanu L; Kovacs K; Aiba T; Sawano S; Shishiba Y
    J Clin Endocrinol Metab; 1993 Feb; 76(2):352-6. PubMed ID: 8432778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?
    Rass L; Rahvar AH; Matschke J; Saeger W; Renné T; Aberle J; Flitsch J; Rotermund R
    Hormones (Athens); 2022 Mar; 21(1):79-89. PubMed ID: 34674191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
    Chahal HS; Trivellin G; Leontiou CA; Alband N; Fowkes RC; Tahir A; Igreja SC; Chapple JP; Jordan S; Lupp A; Schulz S; Ansorge O; Karavitaki N; Carlsen E; Wass JA; Grossman AB; Korbonits M
    J Clin Endocrinol Metab; 2012 Aug; 97(8):E1411-20. PubMed ID: 22659247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
    Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
    Kim CH; Kim J; Kahng H; Choi EC
    Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of octreotide on morphology of pituitary adenomas in acromegaly.
    Sautner D; Saeger W; Tallen G; Lüdecke DK; Rehpenning W
    Pathol Res Pract; 1993 Nov; 189(9):1044-51. PubMed ID: 8302723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.